Bivalent BNT162b2 and the future directions of COVID-19 vaccination


Professor Stephen J. Thomas, MD

Professor of Medicine, Microbiology & Immunology
Frank E. Young, MD '56 and Leanne Young Endowed Chair of Microbiology and Immunology,
Institute for Global Health and Translational Science,

SUNY Upstate Medical University


Since early March 2023 when COVID-19 restriction measures in Hong Kong were abated, a resurgence of local cases, caused predominantly by Omicron XBB and its descendant lineages, has been observed.1,2 Given the enduring threat of COVID-19 infection and long COVID, vaccination remains the key prevention strategy to safeguard public health, particularly the high risk group.  In a recent interview with Omnihealth Practice, Prof. Thomas, Professor of Microbiology and Immunology in SUNY Upstate Medical University, shared his insights on the effectiveness of the new bivalent BNT162b2 vaccine (original/BA.4-5 strains) and the future global vaccination strategies in response to the emerging SARS-CoV-2 variants.

Continue to the article

Get access to our exclusive articles.
Related Articles